PAVmed established an interesting hub and spoke business model with joint services and selling stakes in commercially ready technologies. This opens up new financing streams and potentially a lot of […]
The shares of the company are extremely volatile as visibility into the financial future of the company is limited. However, we do think that, while certainly not devoid of risk, […]
The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage. Yet, like for most pre-revenue medical device […]
The company has a number of products in various states of regulatory approval, each of which have a substantial market opportunity. Commercialization of three of its bigger solutions is imminent […]
The company has a number of products in various stages of regulatory approval, one of which will start to generate revenue within 2-4 weeks. The company has finance lined up […]